Comparative Pharmacology
Head-to-head clinical analysis: FOLIC ACID versus HEXA BETALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLIC ACID versus HEXA BETALIN.
FOLIC ACID vs HEXA-BETALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is a synthetic form of folate, a water-soluble B vitamin. It is reduced to dihydrofolate (DHF) and then to tetrahydrofolate (THF) via dihydrofolate reductase (DHFR). THF serves as a cofactor for one-carbon transfer reactions essential for purine and thymidine synthesis (DNA replication), amino acid metabolism (e.g., homocysteine remethylation to methionine), and other methylation reactions.
Hexa-Betalin is a combination of six B vitamins (B1, B2, B3, B5, B6, B12) that act as cofactors in various enzymatic reactions involved in energy metabolism, neurotransmitter synthesis, and nerve function.
Oral or intramuscular/subcutaneous injection: 400-800 mcg daily for general supplementation; 1-5 mg daily for folate deficiency; 5-15 mg daily for megaloblastic anemia.
Dosage forms: Tablet 10mg, 50mg, 100mg, 250mg; Injection 50mg/mL. Usual adult dose: 100–250mg orally 1–3 times daily. Maximum 1000mg/day. IV/IM: 50–250mg every 6–8 hours as needed.
None Documented
None Documented
Clinical Note
moderateFolic acid + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Folic acid."
Clinical Note
moderateTiaprofenic acid + Folic acid
"The therapeutic efficacy of Folic acid can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Folic acid
"The therapeutic efficacy of Folic acid can be decreased when used in combination with Carprofen."
Clinical Note
moderateCyproterone acetate + Folic acid
Terminal elimination half-life is approximately 0.7 hours (range 0.5-1.0 h) for folic acid; the active metabolite (5-MTHF) has a longer half-life of about 3-4 hours.
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function. This short half-life necessitates frequent dosing for sustained therapeutic effect. Half-life is prolonged in renal impairment.
Primarily renal (urinary) as intact folic acid and metabolites, accounting for 80-90% of the excreted dose; fecal elimination via bile is minor (<10%).
Renal excretion of unchanged drug accounts for 75-85% of the administered dose. Biliary/fecal elimination is minimal, less than 5%.
Category A/B
Category C
Vitamin
Vitamin
"The serum concentration of Folic acid can be decreased when it is combined with Cyproterone acetate."